TSX:IMV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

IMV Inc. operates as a clinical-stage biopharmaceutical company. More Details


Snowflake Analysis

Excellent balance sheet and fair value.


Similar Companies

Share Price & News

How has IMV's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IMV is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: IMV's weekly volatility has decreased from 17% to 9% over the past year.


Market Performance


7 Day Return

5.6%

IMV

-0.5%

CA Biotechs

-0.2%

CA Market


1 Year Return

-15.2%

IMV

11.0%

CA Biotechs

1.4%

CA Market

Return vs Industry: IMV underperformed the Canadian Biotechs industry which returned 11% over the past year.

Return vs Market: IMV underperformed the Canadian Market which returned 1.4% over the past year.


Shareholder returns

IMVIndustryMarket
7 Day5.6%-0.5%-0.2%
30 Day21.2%17.5%2.8%
90 Day6.6%17.2%12.4%
1 Year-15.2%-15.2%11.0%11.0%5.0%1.4%
3 Year-26.0%-26.0%7.6%7.6%13.4%2.7%
5 Year132.6%132.6%28.1%28.1%59.7%35.2%

Long-Term Price Volatility Vs. Market

How volatile is IMV's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is IMV undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IMV (CA$4.69) is trading below our estimate of fair value (CA$19)

Significantly Below Fair Value: IMV is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IMV is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.

PE vs Market: IMV is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMV is good value based on its PB Ratio (6.4x) compared to the CA Biotechs industry average (6.7x).


Next Steps

Future Growth

How is IMV forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

45.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMV's revenue (58.3% per year) is forecast to grow faster than the Canadian market (8% per year).

High Growth Revenue: IMV's revenue (58.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IMV's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has IMV performed over the past 5 years?

-32.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IMV is currently unprofitable.

Growing Profit Margin: IMV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMV is unprofitable, and losses have increased over the past 5 years at a rate of 32.9% per year.

Accelerating Growth: Unable to compare IMV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: IMV has a negative Return on Equity (-69.12%), as it is currently unprofitable.


Next Steps

Financial Health

How is IMV's financial position?


Financial Position Analysis

Short Term Liabilities: IMV's short term assets (CA$65.1M) exceed its short term liabilities (CA$9.3M).

Long Term Liabilities: IMV's short term assets (CA$65.1M) exceed its long term liabilities (CA$9.9M).


Debt to Equity History and Analysis

Debt Level: IMV's debt to equity ratio (19.5%) is considered satisfactory.

Reducing Debt: IMV's debt to equity ratio has reduced from 159.5% to 19.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMV has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if IMV has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is IMV current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMV's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Fred Ors (46 yo)

4.75yrs

Tenure

CA$1,038,263

Compensation

Mr. Frederic Ors, also known as Fred, B.Sc., M.B.A., MSc. M.A. has been Chief Executive Officer of IMV Inc. since April 14, 2016 and served as its President. Mr. Ors served as Acting Chief Executive Office...


CEO Compensation Analysis

Compensation vs Market: Fred's total compensation ($USD815.89K) is above average for companies of similar size in the Canadian market ($USD507.26K).

Compensation vs Earnings: Fred's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Frederic Ors
CEO & Director4.75yrsCA$1.04m0.37%
CA$ 1.1m
Pierre Labbé
Chief Financial Officer3.92yrsCA$702.84k0.22%
CA$ 679.1k
Joanne Schindler
Chief Medical Officer1.17yrsCA$654.32kno data
Marc Jasmin
Senior Director of Investor Relations2.08yrsno datano data
Annie Tanguay
Senior Vice President of Quality & Compliance1yrno datano data
Delphine Davan
Director of Communicationsno datano datano data
Andrew Hall
Chief Business Officer0.17yrno datano data
Marianne Stanford
Vice President of Research & Developmentno datano datano data

1.6yrs

Average Tenure

Experienced Management: IMV's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Frederic Ors
CEO & Director4.75yrsCA$1.04m0.37%
CA$ 1.1m
James Hall
Independent Director10.92yrsCA$135.00k0%
CA$ 0
Shermaine Tilley
Independent Director4.58yrsno datano data
Julia Gregory
Independent Director2.58yrsCA$133.90kno data
Andrew Sheldon
Independent Chairman of the Board4.75yrsCA$199.00k0.15%
CA$ 457.6k
Wayne Pisano
Independent Director9.25yrsCA$142.30k0.12%
CA$ 348.6k
Adekunle Odunsi
Member of Scientific & Clinical Advisory Committeeno datano datano data
David Spaner
Member of Scientific & Clinical Advisory Committeeno datano datano data
Brad Nelson
Member of Scientific & Clinical Advisory Committeeno datano datano data
James Johnston
Member of Scientific & Clinical Advisory Committeeno datano datano data
Grant McFadden
Member of Scientific & Clinical Advisory Committeeno datano datano data
Ramy Ibrahim
Member of Scientific & Clinical Advisory Committeeno datano datano data

4.8yrs

Average Tenure

66.5yo

Average Age

Experienced Board: IMV's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IMV insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.5%.


Top Shareholders

Company Information

IMV Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IMV Inc.
  • Ticker: IMV
  • Exchange: TSX
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$302.592m
  • Shares outstanding: 67.09m
  • Website: https://www.imv-inc.com

Number of Employees


Location

  • IMV Inc.
  • 130 Eileen Stubbs Avenue
  • Suite 19
  • Dartmouth
  • Nova Scotia
  • B3B 2C4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMVTSX (The Toronto Stock Exchange)YesCommon SharesCACADOct 2009
IMVNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDOct 2009
5IV1DB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2009

Biography

IMV Inc. operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company’s delivery platform (DPX) ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/22 23:37
End of Day Share Price2021/01/22 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.